Research & Innovation 2015
18th March 2015
Trent Vineyard, Nottingham
ELRIG conference directors Mike Jowett (Cambridge Bioscience) and Mark Wigglesworth (AstraZeneca) are pleased to announce the 3rd annual Research & Innovation conference, which will be held on March 18th, 2015, at its new venue – Trent Vineyard in Nottingham.
The theme of this year’s conference is “Accelerating early discovery”. The meeting will bring together world class speakers and leading industry experts who will discuss the challenges and opportunities in developing and applying new technologies to improve the success of drug discovery and the way different organisations meet this challenge by bringing their scientists together to stimulate innovation.
The conference will have 3 scientific tracks, each representing a major transformative area for early stage drug discovery:
• New Approaches to Phenotypic Screening – this session will define new thinking in the use of phenotypic screening and the impact novel technologies such as 3D cellular systems, stem cells, Crispr and target deconvolution have on this type of screening strategy.
• Novel Methods for Toxicity Studies – presentations in this track will discuss novel methods and technologies that are being used to better predict compound toxicity and explore how to reduce failure rates by ensuring compound safety and lack of toxicity in early drug development.
• Open Innovation, the Way Forward ? – new for this year, this session will focus on the critical need for open innovation networks and the use of collaborations and joint projects between different academic and industry organisations to make powerful leaps forward for new breakthrough therapies.
Each year, the ELRIG Research & Innovation 1-day conference provides a highly impactful learning and networking opportunity for scientists engaged in early-phase drug discovery whether in Academia, Biotech or Pharma. The scientific sessions will be complemented by a high quality scientific poster session, networking opportunities and a vendor exhibition with over 40 exhibitors, including recently formed companies with new and disruptive emerging technologies.
This is a must-attend event to learn about new state-of-the-art technologies and the latest research and innovation trends in drug discovery!
Post Event Review
The 3rd Annual Research & Innovation Meeting recently held in Nottingham UK was a glowing success! With more than 325 delegates registered – the largest number of delegates to date – the Trent Vineyard was buzzing with activity.
Delegates enjoyed a meeting programme packed full of presentations highlighting ground breaking research and newly published or cutting-edge unpublished data. Kicking off the day was an inspiring Plenary Keynote presentation by Mark Bamford, Director Discovery Partnership Leader at GSK on the topic of Open Innovation. Open innovation was a major theme of the conference along with new approaches to phenotypic screening and novel methods for toxicity studies.
The world-class lineup of speakers from both academia and pharma was complemented by 34 poster presentations. The conference directors selected several posters of extremely high quality for short presentations during the main scientific sessions. Vinoj George of the University of Nottingham, also a session chair for the Phenotypic Screening track, won the award for best poster with his poster entitled, “High Efficiency Differentiation & Maturation of Human Stem Cell (hPSC) – Dervied Cardiomyocytes”.
Exhibitors and Snapshot Sessions:
29 companies exhibited at the event, with 7 up-and-coming companies participating in our Innovation Zone. Many companies selected this venue to showcase their newest technology platforms and product offerings, and as a reward, 10 companies were selected by the scientific committee to give 5 min “Snapshot Presentations” during each of the scientific sessions to discuss their enabling technologies, products or services. Delegates voted for their favorite new technology and awarded the prize to Lablogic for their Hidex Sense Microplate Reader.
Conference directors Mark Wigglesworth (AstraZeneca) and Mike Jowett (Horizon Discovery) were thrilled that the conference achieved one of the main objectives of the ELRIG organisation –that is to make excellent scientific content freely accessible to an ever increasing number of delegates from a diverse range of scientific disciplines and backgrounds.
Delegates commented that R&I 2015 was different from other types of open innovation events in the sense that it was not a typical meeting where large pharma “preaches to the already converted”. Rather, R&I 2015 provided real examples across multiple labs and scientific disciplines that open innovation can work. For the first time ever, delegates enjoyed a presentation about venture capital funding that was directly targeted to the ELRIG audience. In the Phenotypic Screening and Safety & Toxicity tracks, presentations also highlighted how vendors are modifying their detection systems to accommodate the development of more complex, predictive cellular models by researchers. By working together, researchers and vendors can create better assays and solutions to identify compound toxicity issues earlier in the drug discovery process which could ultimately lead to lower attrition rates.
Research & Innovation 2015 – Accelerating Early Discovery
A warm thank you to all our speakers who volunteered their time as well as the tireless efforts of the scientific committee in putting together an amazing scientific program:
– Vinoj George, University of Nottingham
– Gary Allenby, Aurelia Bioscience
– Malcolm Haddrick, AstraZeneca
– Richard Walmsley, University of Manchester
– Ian Waddell, CRUK Manchester Institute
– Timothy Perera, Janssen
Watch for more information on Research & Innovation 2016 at Drug Discovery’15 in September.